Paris, France and Camberley, UK - 29 June 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is to launch two PathFlow® COVID-19 antigen lateral flow tests (LFTs) to strengthen the Company's COVID-19 portfolio and to pursue significant new market opportunities, especially in point-of-care (POC) settings. The Company will initially target private market opportunities for these LFTs via its existing distribution network.

http://novacyt.com/wp-content/uploads/2021/06/Novacyt-Expansion-of-PathFlow®-COVID-19-final.pdf

Attachments

  • Original document
  • Permalink

Disclaimer

Novacyt SA published this content on 29 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 June 2021 06:19:34 UTC.